Gynaecomastia may be due to medication, chronic liver or kidney disease, hypogonadism (primary or secondary to pituitary disease) or hyperthyroidism. Having excluded these aetiologies, it is imperative to be vigilant for underlying malignancy causing gynaecomastia. These include human chorionic gonadotrophin-secreting testicular and extratesticular tumours and oestrogen-secreting testicular tumours and feminising adrenal tumours.
| INTRODUCTION
Gynaecomastia is the benign proliferation of male breast glandular tissue and affects up to two-thirds of adult men.
1 Unlike female breasts, there is no progesterone-induced terminal alveolar development in gynaecomastia. Gynaecomastia should be distinguished from lipomastia (fat deposition or pseudogynaecomastia). The development of subareolar ductular tissue and fibrosis in gynaecomastia produces a firmer consistency compared to adipose tissue. 2 Gynaecomastia may be secondary to medications, chronic liver or kidney disease, hypogonadism (primary or secondary) or hyperthyroidism. In addition, endocrine tumours are an uncommon but important aetiological factor.
| PATHOPHYSIOLOGY
Typically, gynaecomastia arises from an imbalance in the androgenic and oestrogenic effects on breast tissue. 1 Male breast tissue expresses receptors for both androgens and oestrogens. Whilst oestrogens stimulate the proliferation of breast tissue, androgens inhibit proliferation. Hence, conditions which cause an absolute or relative androgen deficiency or an increase in the circulating levels of oestrogens will lead to gynaecomastia. Increased oestrogen concentrations also result in increased SHBG levels, which in turn lead to a reduction in free testosterone, further decreasing the freeandrogen-to-free-oestrogen ratio. Furthermore, luteinising hormone (LH), human chorionic gonadotrophin (hCG), prolactin, progesterone and insulin-like growth factor receptors are expressed in male breast tissue; however, their role in the pathogenesis of gynaecomastia is unclear.
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| EVALUATION OF A PATIENT WITH GYNAECOMASTIA
In all patients presenting with gynaecomastia, a detailed history and examination should be performed. In the majority of cases, gynaecomastia is benign; however, primary breast malignancy should be excluded if there is any suspicion of this by referring urgently to the breast clinic for mammography ± biopsy.
In patients presenting with true gynaecomastia, medications and chronic liver and kidney disease must be excluded as the underlying Circulating oestradiol levels may vary considerably between men, and this variation may be attributed, at least in part, to genetic determinants. 5 Published reference ranges for serum oestradiol in men have been derived using immunoassay. However, recent studies highlight that measured serum oestradiol values in men are dependent on the immunoassay platform used and appear to overestimate the true levels of oestradiol when defined using liquid chromatography-mass spectrometry (LC-MS). It would be advantageous to move towards LC-MS measurement of oestradiol, to allow better diagnostic investigation of men with gynaecomastia.
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Tumours causing gynaecomastia can be divided into hCG-secreting testicular and extratesticular tumours and oestrogen-secreting testicular and adrenal tumours.
| HUMAN CHORIONIC GONADOTROPHIN-SECRETING TUMOURS
Human chorionic gonadotrophin (hCG) has structural similarity with LH and stimulates LH or hCG receptors on Leydig cells in the testes. High hCG levels stimulate the testicular aromatase activity and inhibit the 17, 20-lyase activity. 7 The net result is a relative increase in oestradiol-to-testosterone synthesis. In addition, hCG-secreting tumours may also aromatise circulating steroid precursors, such as dehydroepiandrosterone sulphate (DHEAS), into oestrogens. 8 LH or hCG receptors have also been found in male breast tissue; however, to date, their role in the pathogenesis of gynaecomastia is unclear. 
| Human chorionic gonadotrophin-secreting testicular tumours
Germ cell tumours account for 95% of testicular tumours and affect men in the third and fourth decades of life. 9 The gynaecomastia in germ cell tumours is associated with hCG secretion. Germ cell tumours are divided into seminomas (50%) and nonseminomatous germ cell tumours (50%). Gynaecomastia has been reported in 7% of patients with germ cell tumours, with an approximately equal incidence between seminomas and nonseminomatous germ cell tumours. 10 These testicular tumours are usually aggressive and malignant. 
| Human chorionic gonadotrophin-secreting extratesticular tumours
Gynaecomastia associated with ectopic hCG production from nontesticular tumours (e.g lung, gastric, renal cell and hepatocellular carcinoma) is very rare. Boys with Klinefelter syndrome may uncommonly develop rapidly progressive gynaecomastia due to extragonadal hCGsecreting germ cell tumours in the mediastinum. 
| OESTROGEN-SECRETING TUMOURS

| Oestrogen-secreting testicular tumours
Testicular tumours may elevate circulating oestrogen levels by either secreting oestrogens directly, or by secreting androgens, which are 
| Leydig cell tumours
These account for 0.8%-3% of all testicular tumours and can occur at any age, but particularly in prepubertal boys (5-10 years) and in adults (30-60 years). 9, 13 Leydig cell tumours can directly secrete oestradiol. 14,15 Serum gonadotrophin levels may not be suppressed in patients with Leydig cell tumours. 16 Approximately 15%-30% of Leydig cell tumours present with gynaecomastia. 9 Leydig cell tumours are malignant in 10% of adult cases. 
| Sertoli cell tumours
These account for 0.4%-1.5% of testicular tumours and elevated plasma oestrogen levels may be seen in 11%-25% of patients, which may be associated with gynaecomastia. 18 These tumours have a peak frequency between 35 and 50 years. 19 Distant or lymph node metastases are present in 10%-20% of cases. 
| Oestrogen-secreting adrenal tumours
Most functioning adrenal tumours secrete glucocorticoids. 24, 25 However, 1%-2% of adrenocortical tumours were observed to secrete oestrogens such as oestrone and oestradiol ("feminising adrenal tumours") during a review of 801 adrenalectomies over a 30-year period. 26 Affected men are typically young or middleaged and present with gynaecomastia and clinical features of hypogonadism such as reduced libido and erectile dysfunction. 24, 27, 28 Cushingoid features may also be present if the feminising adrenal tumour cosecretes glucocorticoids. 24, 29 Feminising adrenal tumours are aggressive and malignant. 1 Typically, tumours metastasise to lung, liver and bone and often present with the same hormonal effects as the primary. 24 In a review of 52 cases of feminising adrenal tumours, 98% of patients had gynaecomastia, 58% had a palpable abdominal tumour, 52% had testicular atrophy, 48% had reduced libido and 42% had breast tenderness.
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The evaluation of feminisation should include measurement of oestradiol and oestrone levels. These tumours may secrete oestrogens directly, but may also secrete adrenal androgens (eg, DHEAS and androstenedione), which are aromatised to oestrogens in other tissues. 1 Gonadotrophin levels (LH and FSH) may be normal or low. 24 Ultrasonography of the testes is essential to exclude testicular tumours and may detect testicular atrophy. Abdominal CT scanning is useful in the detection of these often large, poorly differentiated adrenal tumours. All affected patients should be evaluated for clinical features of phaeochromocytoma and cortisol excess. At diagnosis, the majority of patients have extensive local invasion and may have metastases, and therefore, prognosis of feminising adrenal tumours is poor. 1 Surgical resection is the mainstay of treatment.
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It is recommended that surgery is considered if more than 90% of the tumour is resectable, even if functional metastatic disease is present. 24 Case reports suggest that elevated oestradiol and oestrone levels normalise with the feminising syndrome regressing after tumour resection. 24, 31 Historically, mitotane has been shown to be effective in decreasing adrenocortical tumour mass and abnormal steroid production. Tumour response to dexamethasone or a combination of mitotane, fluorouracil and prednisone has also been reported.
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Limited success has been shown with adrenostatic drugs, such as ketoconozaole, metyrapone and etomidate; however, these may be useful if there is cosecretion of cortisol. 32 Feminising adrenal tumours express aromatase mRNA, and aromatase inhibitors (such as anastrozole) may potentially have a therapeutic role in the treatment of these tumours. 24, 31 
